Skip to the page

Data / Drug companies / Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC: 198 products in the FDA NDC directory, labeler code 65219

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Fresenius Kabi USA, LLC (labeler code 65219) lists 198 products in the FDA National Drug Code Directory, covering 71 finished drugs by generic name. By type: 198 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 1, 2026.

The request: Watch Fresenius Kabi USA, LLC (FDA labeler code 65219): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
65219
Products in commercial distribution
198
Packages
214
Finished drugs by generic name
71
Prescription products
198
Over the counter products
0
Controlled substance products
Schedule III 4, Schedule IV 3, Schedule V 1
Flagged as original packager
180 of 180 products that carry the flag
Started marketing in the last 12 months
17
Earliest marketing start
April 1, 2004
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)14573.2%
New drug applications (NDA)2613.1%
Biologics (BLA)2110.6%
Authorized generics (NDA)31.5%
Unapproved drugs for a shortage31.5%

Products by type

TypeProductsShare
Prescription drugs198100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution10251.5%
Injection4824.2%
Injection, powder, for solution115.6%
Injection, powder, lyophilized, for solution115.6%
Injection, solution, concentrate84%
Emulsion84%
Kit63%
Solution21%
Injection, emulsion21%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Nicardipine Hydrochloride65219-298InjectionGeneric drugs (ANDA)October 1, 2026
Nicardipine Hydrochloride65219-296InjectionGeneric drugs (ANDA)October 1, 2026
Glycophos65219-348Injection, solutionNew drug applications (NDA)July 29, 2026
Glycophos65219-346Injection, solutionNew drug applications (NDA)July 29, 2026
Phenylephrine Hydrochloride65219-388InjectionGeneric drugs (ANDA)May 10, 2026
Sodium chloride65219-504Injection, solutionGeneric drugs (ANDA)December 19, 2025
Sodium chloride65219-502Injection, solutionGeneric drugs (ANDA)December 19, 2025
Sterile Water65219-497InjectionGeneric drugs (ANDA)December 19, 2025
Sterile Water65219-495InjectionGeneric drugs (ANDA)December 19, 2025
Levetiracetam65219-046InjectionGeneric drugs (ANDA)December 12, 2025
Levetiracetam65219-044InjectionGeneric drugs (ANDA)December 12, 2025
Levetiracetam65219-042InjectionGeneric drugs (ANDA)December 12, 2025
Ascorbic Acid65219-027InjectionGeneric drugs (ANDA)December 8, 2025
Manganese65219-530Injection, solutionGeneric drugs (ANDA)November 17, 2025
Ustekinumab-aauz65219-866Injection, solutionBiologics (BLA)November 15, 2025
Ustekinumab-aauz65219-862Injection, solutionBiologics (BLA)November 15, 2025
Dalbavancin hydrochloride65219-120Injection, powder, for solutionGeneric drugs (ANDA)November 10, 2025
Otulfi65219-822Injection, solutionBiologics (BLA)September 29, 2025
Tyenne65219-598Injection, solutionBiologics (BLA)September 1, 2025
Tyenne65219-596Injection, solutionBiologics (BLA)September 1, 2025
Ephedrine sulfate65219-548InjectionGeneric drugs (ANDA)July 7, 2025
Ephedrine sulfate65219-546InjectionGeneric drugs (ANDA)July 7, 2025
Bomyntra65219-672InjectionBiologics (BLA)June 30, 2025
Bomyntra65219-670InjectionBiologics (BLA)June 30, 2025
Conexxence65219-668InjectionBiologics (BLA)June 30, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.